Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 3100 of 3499 entries
View as:

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT01222715 Org: User:
Start: 10/31/10 End: 06/30/15 Due: 06/30/16

Determination of HIV-1 Production by the Prostate

Phase: N/A Priority: Normal
NCT ID: NCT00001584 Org: User:
Start: 07/31/97 End: 04/30/01 Due: 04/30/02

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00669019 Org: User:
Start: 07/31/06 End: 01/31/11 Due: 01/31/12

Testing a Spanish Version of a Patient Toxicity Questionnaire

Phase: N/A Priority: Normal
NCT ID: NCT01517152 Org: User:
Start: 01/04/12 End: 10/09/18 Due: 10/09/19

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02890329 Org: User:
Start: 09/05/17 End: 08/19/25 Due: 08/19/26

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT03218826 Org: User:
Start: 09/24/18 End: 10/03/25 Due: 10/03/26

MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01333475 Org: User:
Start: 03/31/11 End: 09/30/14 Due: 09/30/15

Gut Microbiota in People With Hepatocellular Carcinoma (HCC)

Phase: N/A Priority: Normal
NCT ID: NCT02599909 Org: User:
Start: 11/06/15 End: 09/14/18 Due: 09/14/19

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT00082017 Org: User:
Start: 04/05/04 End: 09/27/11 Due: 09/27/12

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01139970 Org: User:
Start: 05/21/10 End: 02/22/26 Due: 02/22/27

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT04396860 Org: User:
Start: 09/01/20 End: 03/11/26 Due: 03/11/27

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00331513 Org: User:
Start: 03/31/06 End: - Due: -

Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01593696 Org: User:
Start: 06/29/12 End: 10/02/17 Due: 10/02/18

Markers for Early Detection of Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00340717 Org: User:
Start: 05/31/03 End: - Due: -

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Phase: N/A Priority: Normal
NCT ID: NCT02304458 Org: User:
Start: 03/30/15 End: 03/31/23 Due: 03/31/24

Extended Follow-up of Columbia, MO Serum Bank Participants

Phase: N/A Priority: Normal
NCT ID: NCT00340210 Org: User:
Start: 01/14/99 End: 09/02/14 Due: 09/02/15

Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00516243 Org: User:
Start: 07/31/07 End: 03/31/10 Due: 03/31/11

GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00074022 Org: User:
Start: 10/31/03 End: - Due: -

Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00095979 Org: User:
Start: 05/31/05 End: 07/31/09 Due: 07/31/10

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT00365157 Org: User:
Start: 10/23/06 End: 09/01/25 Due: 09/01/26

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00475150 Org: User:
Start: 05/31/08 End: 03/31/12 Due: 03/31/13

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05422794 Org: User:
Start: 05/18/23 End: 12/31/25 Due: 12/31/26

BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00022542 Org: User:
Start: 06/30/01 End: 06/30/06 Due: 06/30/07

NCI UNC Project ESCC

Phase: N/A Priority: Normal
NCT ID: NCT03206125 Org: User:
Start: 08/01/17 End: 05/15/20 Due: 05/15/21

Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00004032 Org: User:
Start: 10/31/97 End: - Due: -